about-me variable
Cytonics Corporation invites you to their event

Cytonics Investor Presentation

About this event

Join Joey Bose, President of Cytonics in an exclusive investor webinar to learn more about Cytonics' first-in-class drug development program for inflammatory diseases (osteoarthritis, COVID-19) and investment in the company!

Topics covered:

  • Cytonics' APIC therapy for osteoarthritis and the future of regenerative medicine
  • The development of a first-in-class biologic therapeutic, "CYT-108", for osteoarthritis
  • Preclinical trial results and roadmap to FDA approval for CYT-108
  • CYT-108 as a treatment for COVID-19
  • Investment opportunity in Cytonics

Cytonics is a privately held research and development company developing first-in-class therapeutics for osteoarthritis. The company has treated over 7,000 patients to date with its patented APIC technology, a medical device that concentrates the therapeutic A2M protein from patients' own blood, and delivers the purified A2M concentrate into back into damaged joints. Cytonics is developing a synthetic version of the A2M protein that has been engineered to be more effective than the naturally occurring form. Dubbed "CYT-108", this patented first-in-class therapeutic has shown promising results in preclinical trials and is almost ready to be tested in humans! Cytonics is currently raising capital to fund Phase 1 human clinical trials and further drug development. Learn more here: invest.cytonics.com

Hosted by

  • Team member
    JB T
    Joey Bose

Cytonics Corporation

Developing state-of-the-art diagnostics and therapeutics for osteoarthritis

Cytonics is a leader in the field of regenerative medicine and is positioned to disrupt the space with their innovative biologic therapies for musculoskeletal diseases.